Q11526 (Q11526): Difference between revisions
Jump to navigation
Jump to search
(Removed claims) |
(Changed an Item) |
||||||||||||||
| Property / EU contribution | |||||||||||||||
25,300,500.0 Czech koruna
| |||||||||||||||
| Property / EU contribution: 25,300,500.0 Czech koruna / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / EU contribution | |||||||||||||||
1,012,020.0 Euro
| |||||||||||||||
| Property / EU contribution: 1,012,020.0 Euro / rank | |||||||||||||||
Preferred rank | |||||||||||||||
| Property / EU contribution: 1,012,020.0 Euro / qualifier | |||||||||||||||
exchange rate to Euro: 0.04 Euro
| |||||||||||||||
| Property / EU contribution: 1,012,020.0 Euro / qualifier | |||||||||||||||
point in time: 10 January 2020
| |||||||||||||||
| Property / budget | |||||||||||||||
50,601,000.0 Czech koruna
| |||||||||||||||
| Property / budget: 50,601,000.0 Czech koruna / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / budget | |||||||||||||||
2,024,040.0 Euro
| |||||||||||||||
| Property / budget: 2,024,040.0 Euro / rank | |||||||||||||||
Preferred rank | |||||||||||||||
| Property / budget: 2,024,040.0 Euro / qualifier | |||||||||||||||
exchange rate to Euro: 0.04 Euro
| |||||||||||||||
| Property / budget: 2,024,040.0 Euro / qualifier | |||||||||||||||
point in time: 10 January 2020
| |||||||||||||||
Revision as of 01:08, 12 February 2020
Project in Czech Republic financed by DG Regio
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | No label defined |
Project in Czech Republic financed by DG Regio |
Statements
25,300,500.0 Czech koruna
0 references
50,601,000.0 Czech koruna
0 references
50 percent
0 references
31 March 2020
0 references
Institute of Applied Biotechnologies a.s.
0 references
50°5'1.93"N, 14°30'28.48"E
0 references
10800
0 references
10800
0 references
Záměrem projektu TGM je vytvoření nového pracoviště pro cílené mapování lidského genomu, které bude sloužit k kolaborativnímu vývoji a klinickému výzkumu nových produktů pro stanovení ranných stádií rakoviny s využitím cirkulujících buněk z krve. Plánujeme zásadním způsobem přispět k rozvoji Theranostiky v ČR, tedy terapie založené na diagnostice, která vede k personalizaci zdravotní péče, zvýšení efektivity a cílené terapie a výrazně snižuje léčebné náklady. a. (Czech)
0 references
Identifiers
CZ.01.1.02/0.0/0.0/17_093/0012409
0 references